Skip Navigation



Journal of the National Cancer Institute Advance Access published online on July 8, 2008
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djn194
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Material
Right arrow All Versions of this Article:
100/14/1042    most recent
djn194v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Boneberg, E.-M.
Right arrow Articles by Fürstenberger, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boneberg, E.-M.
Right arrow Articles by Fürstenberger, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

CORRESPONDENCE

Reduced Expression of Cyclooxygenase-2 in Primary Breast Cancer

Eva-Maria Boneberg, Daniel F. Legler, Hans-Jörg Senn, Gregor Fürstenberger

Affiliations of authors: Biotechnology Institute Thurgau at the University of Konstanz, Kreuzlingen, Switzerland (EMB, DFL, HJS, GF); Tumor Center ZeTuP, St Gallen, Switzerland (EMB, DFL, HJS, GF); Tumor Center ZeTuP, Chur, Switzerland (EMB, DFL, HJS, GF)

Correspondence to: Gregor Fürstenberger, MD, Tumor Center ZeTuP, Rorschacherstrasse 150, 9006 St Gallen, Switzerland (e-mail: gfuerstenberger@gr.zetup.ch).

The first 10% of the full text of this article appears below.

Recently reported results of a phase 2 study combining the aromatase inactivator exemestane with the cyclooxygenase-2 (COX-2) inhibitor celecoxib for the treatment of breast cancer showed that patients receiving the combined treatment had response rates and clinical benefit rates that were similar to those of the group receiving exemestane only (1). The rationale for using a COX-2 inhibitor for the treatment of breast cancer is based on several reports that . . . [Full Text of this Article]

Funding


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
C. Falandry, P. A. Canney, G. Freyer, and L. Y. Dirix
Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer
Ann. Onc., April 1, 2009; 20(4): 615 - 620.
[Abstract] [Full Text] [PDF]